Cidofovir how supplied

Revision as of 02:37, 3 January 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Cidofovir}} {{CMG}} ==How Supplied== VISTIDE (cidofovir injection) 75 mg/mL for intravenous infusion, is supplied as a non-preserved solution in single-use clear ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Cidofovir
VISTIDE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

How Supplied

VISTIDE (cidofovir injection) 75 mg/mL for intravenous infusion, is supplied as a non-preserved solution in single-use clear glass vials as follows:

NDC 61958-0101-1 375 mg in a 5 mL vial in a single-unit carton

VISTIDE should be stored at controlled room temperature 20–25 °C (68–77 °F).

VISTIDE® (cidofovir injection) is covered by U.S. Patent No. 5,142,051 and its foreign counterparts. Other patents pending.[1]

References

  1. "http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/020638s003lbl.pdf" (PDF). External link in |title= (help)

Adapted from the FDA Package Insert.